Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768088 | 0.91 | DYRK1A (0.36) | DYRK1ASTING1KMT2AMEN1EDNRA | |
| SCHEMBL4772079 | 0.89 | NMT1 (0.36) | DYRK1AKMT2AMEN1EDNRAALDH1A1 | |
| SCHEMBL4762820 | 0.85 | STING1 (0.43) | DYRK1ASTING1KMT2AEDNRAALDH1A1 | |
| SCHEMBL4768131 | 0.84 | STING1 (0.43) | DYRK1ASTING1KMT2AEDNRAALDH1A1 | |
| SCHEMBL4770165 | 0.82 | PIK3CD (0.37) | DYRK1ASTING1KMT2AMEN1EDNRA | |
| SCHEMBL6026774 | 0.80 | EDNRA (0.36) | DYRK1ASTING1KMT2AEDNRAMAPK1 | |
| SCHEMBL4771792 | 0.80 | DYRK1A (0.36) | DYRK1ASTING1KMT2AMEN1EDNRA | |
| SCHEMBL4771984 | 0.79 | EDNRA (0.37) | DYRK1ASTING1KMT2AMEN1EDNRA | |
| SCHEMBL5227613 | 0.78 | STING1 (0.52) | DYRK1ASTING1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4766085 | 0.76 | EDNRA (0.47) | DYRK1AEDNRASMN1; SMN2ALDH1A1ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1636212-B1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO¬B|THIOPHENES AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| EP-1636212-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2004108714-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | claimed |
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-12-09 | — | — | US | claimed |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | disclosed |
| EP-1636212-B1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO¬B|THIOPHENES AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1636212-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108714-A1 | CYCLOALKYLSULFANYL SUBSTITUTED BENZO[B]THIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248954-A1 | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents | MALT1, BPNT1, CYP1B1 | DYRK1A 3978/4885STING1 2995/4885KMT2A 3569/4885 |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | PI4KB, PIK3CA, PI4KA | DYRK1A 1368/4885STING1 915/4885KMT2A 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.